Trial Profile

Multicenter Phase II Clinical Study on the Safety and Efficacy of Nilotinib in Patients with Chronic Myelogenous Leukemia, Chronic Phase Patients with Major Molecular Response.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Sep 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Aug 2018 Primary endpoint (CMR rate at 24 months after the initiation of nilotinib treatment) has been met as per results published in the International Journal of Hematology.
01 Aug 2018 Results published in the International Journal of Hematology
25 Jun 2017 Results of association of nilotinib trough concentraion and liver dysfunction data from two studies (STAT1 and STAT2) presented at the 22nd Congress of the European Haematology Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com